Novel Off-label Use of Desipramine in Infantile Neuroaxonal Dystrophy: Targeting the Sphingolipid Metabolism Pathway to Reduce Accumulation of Ceramide.

This is a research study to find out if clinically prescribed desipramine is effective at improving the symptoms and slowing the progression of Infantile Neuroaxonal Dystrophy (INAD) in affected children.
Participants will receive an initial oral dose of study drug once a day. This dose may be changed depending on response to study drug Clinically collected data will be recorded for up to 5 years. Investigators will also ask for participant permission to obtain a sample of child's skin biopsy from unused clinical sample previously collected for standard of care.

Start Date14 Jan 2019

Sponsor / Collaborator

Duke University

NCT03548454

/ CompletedPhase 4IIT

Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization

Over 100 million Americans suffer from chronic pain resulting in annual cost of roughly $635 billion. Limited treatments are available for this widespread disease. The data supporting these treatments lack generalizability to patients with more serious medical and psychological comorbidities who are often excluded from explanatory efficacy trials. Our work aims to integrate randomized comparative effectiveness research with patient care. The investigators will randomize the patients and collect data using an open-source learning healthcare system already in use in our department to monitor patients' progress: Collaborative Health Outcomes Information Registry (CHOIR). Collaborative Health Outcomes Information Registry uses the National Institute of Health Patient Reported Outcomes Measurement Information System item banks for comparative metrics through computer adaptive testing. The investigators will leverage the advantage of this novel system to compare effectiveness of duloxetine and desipramine in decreasing pain in patients with chronic pain. The investigators will also compare adherence of patients to these two commonly used medications over a period of six months. This will evaluate feasibility of integrating randomized comparative effectiveness research with patient care in subspecialty clinics. Collaborative Health Outcomes Information Registry can then be applied for numerous future trials to advance our knowledge in perioperative and pain medicine.

Start Date20 Sep 2018

Sponsor / Collaborator

Stanford University

100 Clinical Results associated with Desipramine Hydrochloride

100 Translational Medicine associated with Desipramine Hydrochloride

100 Patents (Medical) associated with Desipramine Hydrochloride

8,117

Literatures (Medical) associated with Desipramine Hydrochloride

01 Dec 2026·Current Pain and Headache Reports

Periosteal Osteosarcoma: Emerging Clinical Concepts, Evolving Treatment Options: A Narrative Review

Review

Author: Kaye, Alan D ; Bratton, Matthew B ; Shekoohi, Sahar ; Islam, Rahib K ; Pirzadah, Humza A ; Abd-Elsayed, Alaa ; Starns, Michael J

PURPOSE OF REVIEW:

Periosteal osteosarcomas are rare bone tumors that comprise less than 2% of all bone malignancies. The tumor was previously thought to affect the diaphysis of long bones solely, but Recent case reports have demonstrated its existence in the clavicle, mandible, and scapula.

RECENT FINDINGS:

Several factors, including stage, grade, and medullary invasion primarily drive survival and recurrence of periosteal osteosarcomas. Related to its rarity, little data currently exists regarding optimum treatment strategies, including limb amputation, surgical resection, and chemotherapy in the neoadjuvant/adjuvant setting. In this regard, bone pain is the most common manifestation. Pain treatment can include medications such as oral or transdermal opioids. Adjuvant drugs can reduce inflammation and neuropathic pain, including corticosteroids, gabapentinoid agents such as gabapentin or pregabalin, lidocaine patches, tricyclic antidepressants such as amitriptyline, nortriptyline, and desipramine, or selective serotonin-norepinephrine reuptake inhibitors such as duloxetine and venlafaxine. More advanced pain treatment interventions can be provided by interventional pain medicine physicians, such as radiofrequency ablation, peripheral nerve stimulation, spinal cord stimulation, or intrathecal drug delivery systems, when conventional opioids and adjuvants do not adequately provide relief. Molecular workups of case reports have shown common mutations, such as the p53 gene, which may provide utility for future molecular targets. The present investigation aims to synthesize currently available data on periosteal osteosarcomas, including common clinical, histologic, and radiographic presentations. In addition, this review aims to further examine the potential for biomarkers and provide recommendations for treatment and future research direction.

01 Sep 2026·COLLOIDS AND SURFACES B-BIOINTERFACES

ROS-responsive hydrogel for treating pulpitis: Localized immunometabolic regulation by dimethyl itaconate promotes reparative dentin formation

Article

Author: Li, Weichang ; Cai, Luhui ; Li, Yue ; Ni, Zihan ; Ding, Wenqian ; Tsai, I-Chen ; Xu, Qiong ; Tian, Cheng

Pulpitis is a common inflammatory disease of the dental pulp in which excessive inflammation and oxidative stress severely compromise the regenerative capacity of dental pulp stem cells (DPSCs), posing a major challenge for successful vital pulp therapy. Herein, we report an immunometabolic strategy that combines dimethyl itaconate (DMI) with a reactive oxygen species (ROS)-responsive injectable hydrogel to modulate the inflammatory microenvironment and promote functional pulp regeneration. We demonstrated that DMI effectively suppressed lipopolysaccharide (LPS)-induced inflammatory cytokine expression and ROS accumulation in DPSCs. Notably, DMI did not directly enhance odontogenic differentiation under inflammatory conditions; instead, it indirectly restored the odontogenic potential of DPSCs by attenuating macrophage-mediated inflammation. To enable localized and sustained delivery of DMI, a dual-crosslinked SADA/CMBA hydrogel was developed based on dynamic boronic ester bonds and ionic coordination, allowing ROS-triggered drug release while maintaining structural integrity and biocompatibility. In vitro studies confirmed the hydrogel's favorable cytocompatibility, anti-inflammatory and antioxidant effects. Furthermore, in an LPS-induced rat pulpitis model, the DMI-loaded hydrogel significantly reduced pulpal inflammation and facilitated reparative dentin formation at the pulp exposure site. Collectively, this study introduces an immunometabolic and microenvironment-responsive therapeutic design for pulpitis treatment and highlights the potential of ROS-adaptive biomaterials to enhance the outcomes of vital pulp therapy.

01 Aug 2026·JOURNAL OF CONTROLLED RELEASE

Bio-derived solvents for in situ forming implants

Article

Author: Meakin, Ashley S ; Bobrovskaya, Larisa ; Bradshaw-Hajek, Bronwyn H ; Blencowe, Anton ; Bazeed, Alaa Y ; Prestidge, Clive A ; Wignall, Anthony ; Wiese, Michael D ; Morrison, Janna L

In situ forming implants (ISFIs) have gained considerable attention over the past decade as minimally invasive long-acting injectable systems for localised and sustained drug delivery. N-Methyl-2-pyrrolidone (NMP) remains the most commonly used solvent for ISFIs; however, concerns regarding its environmental toxicity and teratogenicity have driven the search for alternatives. Therefore, in this study, we investigated bio-derived and bio-renewable solvents - dimethyl isosorbide (DMI) and γ-valerolactone (GVL) - as potential substitutes for NMP. ISFI formulations were individually prepared with each solvent and poly(lactic-co-glycolic acid) (PLGA; L/G 1:1, 10 kDa) at polymer concentrations of 20, 30, and 40% w/w, and containing 1% w/w eosin Y dye as a model hydrophilic drug. ISFIs were subsequently evaluated for their rheological behaviour, injectability, implant morphology, and dye and solvent release. Rheological analyses revealed solvent-dependent differences, with GVL exhibiting flow behaviour comparable to NMP, while DMI showed significantly higher viscosity. These trends translated into injectability performance. Post-injection, NMP- and DMI-based ISFIs formed spherical implants, whereas GVL-based ISFIs produced collapsed and irregular structures. Moreover, in vitro release studies of eosin Y showed that GVL-based ISFIs significantly reduced burst release while exhibiting overall faster release kinetics, which was attributed to rapid polymer solidification and collapsed implant morphology that shortened diffusion path lengths. A two-stage model was developed to fit the release profiles and determine the average diffusion coefficients (D), allowing a quantitative comparison of the different formulations. To compare the performance of the solvents in vivo in rats, ISFI formulations were prepared containing testosterone (2.5% w/w) as a clinically relevant hydrophobic drug. Testosterone release from DMI- and GVL-based ISFIs was comparable to NMP, although NMP formulations resulted in lower overall plasma concentrations. This study highlights the potential of DMI and GVL as alternative solvents for ISFIs, with comparable performance to the traditionally used NMP.

News (Medical) associated with Desipramine Hydrochloride

06 May 2024

·www.biospace.com

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1 DMI is a common, irreversible complication of diabetic retinopathy (DR) that may lead to blindness.12,3,4 It can develop when the light sensitive tissues of the central retina do not receive adequate blood supply over a longer time. There are currently no approved treatments for DMI. The current standard of care for advanced DR includes intravitreal anti-VEGF treatment or invasive laser treatment. However, some patients’ conditions progress despite this treatment.5 BI 764524 uses a novel mode of action by inhibiting the Sema3A pathway to re-vascularize ischemic areas and potentially overcome the limitations of anti-VEGF and laser treatments.1 “The results from the HORNBILL study are really encouraging. They suggest there may be a pathway for earlier intervention that could decrease the risk of, and maybe even prevent, people with diabetic retinopathy from developing irreversible and vision-threatening complications, such as DMI,” said Quan Dong Nguyen, MD, MSc, FARVO, FASRS, Professor of Ophthalmology at the Byers Eye Institute, Professor of Medicine and of Pediatrics at Stanford School of Medicine, and Principal and Coordinating Investigator of the trial. “Retinal non-perfusion is a key driver of vision loss in people living with diabetic retinopathy. However, until the HORNBILL study, retinal non-perfusion has not been explored as a potential treatment target.” “Vision loss associated with retinal conditions such as diabetic retinopathy and DMI has a devastating impact on quality of life. Today’s results are an important step towards achieving our aspiration of developing precision therapies delivering the right treatment for the right patient at the right time to prevent vision loss before irreversible damage occurs,” said Ulrike Graefe-Mody, Ph.D., Head of Retinal Health at Boehringer Ingelheim. “We’re looking forward to start a Phase IIb study to further explore the safety and efficacy of BI 764524.” HORNBILL is one of 23 abstracts being presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual meeting 2024, spanning Boehringer Ingelheim’s retinal health portfolio, including other studies of retinal non-perfusion and diabetic retinopathy, geographic atrophy and neovascular age-related macular degeneration. About the HORNBILL study The HORNBILL study consisted of two parts (single rising dose (SRD), N=12 and multiple dose (MD), N=31) both of which met the primary safety endpoints of number of patients with dose-limiting adverse events (SRD) and treatment-related adverse events(MD).1 The study also met its pre-specified criterion for early efficacy of foveal avascular zone area stabilization versus sham at week 16 (p<0.2).1 This suggests that BI 764524 may positively impact retinal non-perfusion and potentially halt the progression of capillary loss.1 The upcoming CRIMSON trial, a Phase IIb trial, will assess safety and efficacy of BI 764524 in patients with DR further and start recruiting later this year. Notes to Editors: About the trial (NCT04424290) This Phase I/IIa trial assessed the tolerability of BI 764524 in people with diabetic retinopathy (DR) with diabetic macular ischemia (DMI) who have previously been treated with panretinal photocoagulation.1 The trial consisted of a single rising dose (SRD) part followed by a multiple dosing (MD) part, with BI 764524 administered via intravitreal injection.1 Single rising dose part In the non-randomized, open-label, SRD part, 12 patients received intravitreal BI 764524 doses: 0.5 (n=3), 1.0 (n=3), or 2.5 mg (n=6).1 The primary endpoint was the number of patients with dose-limiting events (DLEs); secondary endpoints were the number of patients with drug-related adverse events (AEs) and any ocular AEs.1 Patients in the SRD part had a mean age of 61.8 years.1 No DLEs were reported in the SRD part.1 There were five ocular AEs in four patients in the study eye, none related to the study drug. The highest tested dose (BI 764524 2.5 mg) was considered safe and applied in the MD part.1 Multiple dosing part In the randomized, masked, sham-controlled, MD part, 31 patients received three intravitreal doses of BI 764524 2.5 mg (n=21) or sham injection procedures (n=10) at 4-week intervals (baseline, week 4, and week 8), followed by 14 weeks of follow-up until the end of study at week 22.1 The primary endpoint was the number of patients with drug-related AEs; secondary endpoints included number of patients with ocular AEs, change from baseline in foveal avascular zone (FAZ) area, best corrected visual acuity (BCVA) and central retinal thickness (CRT).1 Patients in the MD part had a mean age of 59.5 years.1 There were seven patients with ocular AEs (study eye; three patients with four AEs for BI 764524, four patients with six AEs for sham), one of which was reported as related to the study drug (vitreous floater).1 In addition, there was one systemic AE (increase deemed related to the study drug by the investigator). There were no cases of intraocular inflammation or occlusive retinal vasculitis.1 At baseline, mean BCVA was 65.2 letters, mean FAZ area was 0.65 mm, and mean CRT was 252 mm.1 The HORNBILL study met its pre-specified criterion for early efficacy of FAZ area stabilization versus sham at week 16 (p<0.2). Over the short trial period, other secondary efficacy endpoints showed no relevant change. About BI 764524 BI 764524 is a humanized monoclonal anti-Sema3A antibody intended to re-vascularize ischemic areas and reduce leakage in the retina, offering the potential to address retinal non-perfusion in retinal diseases. The compound was discovered and developed by Boehringer Ingelheim and is part of its research and development portfolio in retinal conditions. About diabetic retinopathy and diabetic macular ischemia Diabetic retinopathy affects 1 in 3 people with diabetes and is the leading cause of vision loss in adults of working age. It is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe. Diabetic macular ischemia (DMI) is a complication of diabetic retinopathy which can lead to slowly progressing, irreversible vision loss. About Boehringer Ingelheim Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at Boehringer Ingelheim’s Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. References 1 Nguyen QD, Jhaveri C, Habib MS. Oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024. Abstract number: 959 2 Marques IP, et al. Diabetes 2019;68:648–653 3 Sim DA, et al. Invest Ophthalmol Vis Sci 2013;54:2353–2360 4 Tey KY, et al. Eye Vis (Lond) 2019;6:37 5 Ip MS, et al. Ophthalmology 2014;122:367–374

Clinical ResultPhase 2

22 Nov 2023

·www.prnewswire.com

Novel MRI Reveals Brain Changes in Long-COVID Patients

CHICAGO, Nov. 22, 2023 /PRNewswire/ -- People with long COVID exhibit patterns of changes in the brain that are different from fully recovered COVID-19 patients, according to research being presented next week at the annual meeting of the Radiological Society of North America (RSNA). "To the best of our knowledge, this is the first study comparing patients with long COVID to both a group without history of COVID-19 and a group that went through a COVID-19 infection but is subjectively unimpaired," said one of the study's lead authors, Alexander Rau, M.D., resident in the Departments of Neuroradiology and Diagnostic and Interventional Radiology at University Hospital Freiburg in Freiburg, Germany. After infection with COVID-19, as many as 10-25% of patients may develop a post-COVID condition commonly referred to as "long COVID." People with long COVID may experience a wide variety of symptoms, including difficulty concentrating ("brain fog"), change in sense of smell or taste, fatigue, joint or muscle pain, shortness of breath, digestive symptoms, and more. These symptoms may persist for weeks, months, or—as is only now becoming apparent—years after COVID-19 infection. However, the basis of this condition is poorly understood. Diffusion microstructure imaging (DMI), a novel MRI technique, is a promising approach to fill this gap. DMI looks at the movement of water molecules in tissues. By studying how water molecules move in different directions and at various speeds, DMI can provide detailed information on the microstructure of the brain. It can detect even very small changes in the brain, not detectable with conventional MRI. For this prospective, cross-sectional study, Dr. Rau and colleagues compared MRI brain scans of three groups: 89 patients with long COVID, 38 patients that had contracted COVID-19 but did not report any subjective long-term symptoms, and 46 healthy controls with no history of COVID-19. The researchers first compared the cerebral macrostructure of these three groups to test for atrophy or any other abnormalities. Next, they used DMI to gain a deeper insight into the brain. The three groups were compared to reveal group differences in the brain's microstructure. DMI parameters were read for the gray matter in the brain. Additionally, whole brain analyses were employed to reveal the spatial distribution of alterations and associations with clinical data, including long-COVID symptoms like fatigue, cognitive impairment or impaired sense of smell. The results showed no brain volume loss or any other lesions that might explain the symptoms of long COVID. However, COVID-19 infection induced a specific pattern of microstructural changes in various brain regions, and this pattern differed between those who had long COVID and those who did not. "This study allows for an in vivo insight on the impact of COVID-19 on the brain," Dr. Rau said. "Here, we noted gray matter alterations in both patients with long-COVID and those unimpaired after a COVID-19 infection. Interestingly, we not only noted widespread microstructural alterations in patients with long COVID, but also in those unimpaired after having contracted COVID-19." The findings also revealed a correlation between microstructural changes and symptom-specific brain networks associated with impaired cognition, sense of smell and fatigue. "Expression of post-COVID symptoms was associated with specific affected cerebral networks, suggesting a pathophysiological basis of this syndrome" Dr. Rau said. The researchers hope to reexamine the patients in the future, recording both clinical symptoms and changes to the brain's microstructure. Despite these brain imaging findings, it remains unclear why some people develop long COVID while others do not, although previous studies have identified risk factors including female sex, older age, higher body mass index, smoking, preexisting comorbidities, and previous hospitalization or intensive care unit admission. Co-authors are Jonas A. Hosp, M.D., Nils Schroter, M.D., Marco Reisert, Ph.D., Horst Urbach, M.D., Cornelius Weiller, M.D., and Elias Kellner, Ph.D. Note: Copies of RSNA 2023 news releases and electronic images will be available online at RSNA.org/press23. RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org) Editor's note: The data in these releases may differ from those in the published abstract and those actually presented at the meeting, as researchers continue to update their data right up until the meeting. To ensure you are using the most up-to-date information, please call the RSNA Newsroom at 1-312-791-6610. For patient-friendly information on brain MRI, visit RadiologyInfo.org. SOURCE Radiological Society of North America (RSNA)

Clinical Result

04 Apr 2023

·www.sciencedaily.com

DMI allows magnon-magnon coupling in hybrid perovskites

An international group of researchers has created a mixed magnon state in an organic hybrid perovskite material by utilizing the Dzyaloshinskii--Moriya-Interaction (DMI). The resulting material has potential for processing and storing quantum computing information. An international group of researchers has created a mixed magnon state in an organic hybrid perovskite material by utilizing the Dzyaloshinskii-Moriya-Interaction (DMI). The resulting material has potential for processing and storing quantum computing information. The work also expands the number of potential materials that can be used to create hybrid magnonic systems. In magnetic materials, quasi-particles called magnons direct the electron spin within the material. There are two types of magnons -- optical and acoustic -- which refer to the direction of their spin. "Both optical and acoustic magnons propagate spin waves in antiferromagnets," says Dali Sun, associate professor of physics and member of the Organic and Carbon Electronics Lab (ORaCEL) at North Carolina State University. "But in order to use spin waves to process quantum information, you need a mixed spin wave state." "Normally two magnon modes cannot generate a mixed spin state due to their different symmetries," Sun says. "But by harnessing the DMI we discovered a hybrid perovskite with a mixed magnon state." Sun is also a corresponding author of the research. The researchers accomplished this by adding an organic cation to the material, which created a particular interaction called the DMI. In short, the DMI breaks the symmetry of the material, allowing the spins to mix. The team utilized a copper based magnetic hybrid organic-inorganic perovskite, which has a unique octahedral structure. These octahedrons can tilt and deform in different ways. Adding an organic cation to the material breaks the symmetry, creating angles within the material that allow the different magnon modes to couple and the spins to mix. "Beyond the quantum implications, this is the first time we've observed broken symmetry in a hybrid organic-inorganic perovskite," says Andrew Comstock, NC State graduate research assistant and first author of the research. "We found that the DMI allows magnon coupling in copper-based hybrid perovskite materials with the correct symmetry requirements," Comstock says. "Adding different cations creates different effects. This work really opens up ways to create magnon coupling from a lot of different materials -- and studying the dynamic effects of this material can teach us new physics as well." The work appears in Nature Communications and was primarily supported by the U.S. Department of Energy's Center for Hybrid Organic Inorganic Semiconductors for Energy (CHOISE). Chung-Tao Chou of the Massachusetts Institute of Technology is co-first author of the work. Luqiao Liu of MIT, and Matthew Beard and Haipeng Lu of the National Renewable Energy Laboratory are co-corresponding authors of the research.

100 Deals associated with Desipramine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00812	Desipramine Hydrochloride	N06AA01	DB01151

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder	United States	Validus Pharmaceuticals LLC	20 Nov 1964

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03548454 (CTgov)	Phase 4	Chronic Pain	86	Desipramine (Desipramine)	wcytlusiuu = xjtnkmjmwu ekduspthmw (xdtqlpclok, htlecxhexh - cnsddlhldf) View more	-	06 Nov 2025
				Duloxetine (Duloxetine)	wcytlusiuu = dvomhtkkao ekduspthmw (xdtqlpclok, ghiqguwrfz - jawprluukb) View more
NCT01899326 (CTgov)	Not Applicable	Refractory Multiple Myeloma	10	Laboratory Biomarker Analysis+Filgrastim+Desipramine Hydrochloride	cycyktjdzb = lpyutblegg rmyplcidpu (rrqhkffvvc, girshoonzr - zluybdqucj) View more	-	28 Mar 2023
NCT03726996 (CTgov)	Phase 4	Neuroaxonal Dystrophies	4	Desipramine	mgdkzmgbmz = ahdietwybq scnhzmvnus (vruzppifpn, ztbjsxsyna - fptpjmirib) View more	-	14 Oct 2020
NCT01411085 (RADIAUS, CTgov)	Phase 2	Alcoholism \| Schizophrenia	12	Risperidone+Desipramine	kogbjhivjl(dwodhaksoo) = wmzqvniudz ehkmkmrofb (paqxknjvwy, 20.4) View more	-	23 Mar 2018
NCT00990691 (Pubmed \| Ann Clin Transl Neurol)	Phase 2	Rett Syndrome	36	high Desipramine	nnotducnke(qcwfoqgpkp) = mmsysqghyl isclcebfex (gyegzcbaxq, -37 to -11)	Negative	01 Feb 2018
				low Desipramine	nnotducnke(qcwfoqgpkp) = zrfqejooai isclcebfex (gyegzcbaxq, -31 to 13)
NCT01719861 (CTgov)	Phase 2	Small Cell Lung Cancer \| Neuroendocrine Tumors	6	Desipramine HCL	qxanqlqeni(asfblzsjgs) = skqoryvins tcvtbqzomy (hozrqbyuhj, nrzqkhmevm - yumlyywvat) View more	-	17 Apr 2017
NCT02428478 (DESOSA, CTgov)	Phase 2	Sleep Apnea, Obstructive	17	Desipramine (Desipramine)	pvcgvhbsdz(exbapxzfme) = gqbtaisutu zausibdsnv (ojnqsxvaoe, cyhdfuunql - wmojgbfdqv) View more	-	30 Mar 2017
				Placebo+desipramine (Placebo)	pvcgvhbsdz(exbapxzfme) = eilwpszzxv zausibdsnv (ojnqsxvaoe, erwfumsjrs - loryhgxqin) View more
NCT02436031 (DESOSA, CTgov)	Phase 2	Sleep Apnea, Obstructive	16	Desipramine (Desipramine)	abgcxnvesk(vvqztxpdil) = wpvutrpzkn vhjlckxtup (publwisymf, urtoyijgoe - gyyizvxupe) View more	-	30 Mar 2017
				Placebo+desipramine (Placebo)	abgcxnvesk(vvqztxpdil) = nwgktvubco vhjlckxtup (publwisymf, ujhucvdrhn - cxbdxlmngl) View more
NCT00166114 (CTgov)	Phase 4	Depressive Disorder, Major	40	Escitalopram (Escitalopram)	cfluekdnjp = pmqvppvnkh sidzjvvejh (lxsuilhqai, dcrywkrxmy - oesgnbvyfe) View more	-	23 Jul 2015
				Desipramine (Desipramine)	cfluekdnjp = qvdvqhsbxu sidzjvvejh (lxsuilhqai, objsmpmpmw - hoepnigbfg) View more
NCT00276068 (Pubmed \| Obstet Gynecol)	Not Applicable	Vulvodynia	133	Placebo tablets-Placebo cream	objqlyvmtz(cdamzjqygq) = drmpadhqyl ilfwddmqaw (elqsxqnpnw )	-	01 Sep 2010
				Desipramine tablets-Placebo cream	objqlyvmtz(cdamzjqygq) = tqudapocsg ilfwddmqaw (elqsxqnpnw )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis